Dr Stefan D. Anker is Professor of (Tissue)Homeostasis in Cardiology & Metabolism (W3) at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was Professor of Cardiology & Cachexia Research (W2) at Charité (2002-14), and Professor of Innovative Clinical Trials (W3) in Göttingen (2014-17).
Dr. Anker has authored more than 750 original papers, reviews, and editorials that are well cited (total citations: >51,000, h-index: 108, papers with ≥ 200 citations: 62; source: Scopus, 28th Sept, 2017). For his work Dr. Anker has won several prizes, and obtained a number of fellowships and grants, including 2 from NIH (WARCEF trial), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for “SICA-HF” study (EU-FP7).
Dr. Anker is Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board since 2012. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14), and currently chairpersons the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open access heart failure journal ESC Heart Failure. Dr. Anker serves on the editorial boards of 4 scientific journals (including European Heart Journal and European Journal of Heart Failure), and he worked in several ESC Guideline task forces.
Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle (JCSM, 2016-IF: 9.70, see www.jcsm.info). Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, RESHAPE-HF2, EMPEROR-HFpEF, Fair-HFpEF) as well as in the past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, IMPULSE-HF, and BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).